Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Completed · Phase 3

Conditions studied: GERD

In brief

This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess the efficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.

Key facts

Study ID

NCT00241514

Run by

AstraZeneca

People needed

334

Starts

2001-02-01

Expected to finish

2003-02-01

Last updated by the study team

2011-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent.
• Completed the SH-NEN-0001 study with relief of upper GI symptom. Relief is defined as "last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period".
• A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs.
• Daily NSAID treatment dose and type: (Must have been stable for at least 9 weeks prior to inclusion and; Are expected to remain stable for the duration of the study. and; Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally).
• Hp negative on Histology performed at baseline endoscopy in the study SHNEN- 0001.

You may not qualify if…

• Discontinuation from study SH-NEN-0001
• Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation.
• Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs.
• Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator.
• Need for continuous concomitant therapy with: (Anticoagulants; Corticosteroids at doses higher than explained under inclusion criterion)

Where it is running

• Research Site — Anaheim, California, United States
• Research Site — Orange, California, United States
• Research Site — San Francisco, California, United States
• Research Site — Bradenton, Florida, United States
• Research Site — Clearwater, Florida, United States
• Research Site — Fort Lauderdale, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — South Miami, Florida, United States
• Research Site — West Palm Beach, Florida, United States
• Research Site — Zephyrhills, Florida, United States
• Research Site — Conyers, Georgia, United States
• Research Site — Newburgh, Indiana, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Winston-Salem, North Carolina, United States
• Research Site — Tulsa, Oklahoma, United States
• Research Site — Tipton, Pennsylvania, United States
• Research Site — Norfolk, Virginia, United States
• Research Site — Virginia Beach, Virginia, United States
• Research Site — Alleur, Belgium
• Research Site — Ans, Belgium
• Research Site — Beernem, Belgium
• Research Site — Betekom, Belgium
• Research Site — Bottelare, Belgium
• Research Site — Braine-l'Alleud, Belgium
• Research Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.